Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598962 · ClinicalTrials.gov registry record · Phase 4
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
A Phase 4 study, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00598962: Completed Phase 4 study, sponsored by The University of Texas Health Science Center at Tyler.
NCT00598962 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598962, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
Primary Outcome
neg cultures X3 ( sputum conversion)
Interventions
- DRUG Azithromycin
- DRUG Rifabutin/rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1994-12 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 4 |
What the finished NCT00598962 record still lists
NCT00598962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Azithromycin is the first listed.
NCT00598962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00598962 about?
NCT00598962 is a clinical study titled "Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease". To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
What is the current status of trial NCT00598962?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 1994-12. Estimated completion is 2017-05-18.
What interventions are being tested in trial NCT00598962?
The interventions under investigation include: Azithromycin (DRUG), Rifabutin/rifampin (DRUG).
Who is sponsoring clinical trial NCT00598962?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00598962's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia